Esperion to Report Third Quarter 2025 Financial Results on November 6
Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.
Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.
Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.
Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.
Esperion (NASDAQ: ESPR) reportará los resultados financieros del tercer trimestre de 2025 antes de la apertura del mercado el jueves 6 de noviembre de 2025.
La dirección realizará una transmisión en vivo a las 8:00 a.m. hora del Este para discutir los resultados y las actualizaciones del negocio; una repetición estará disponible aproximadamente a las dos horas después de la llamada y quedará archivada en el sitio web de la empresa por unos 90 días.
Esperion es una empresa biofarmacéutica en etapa comercial que comercializa las únicas terapias orales no estatinás aprobadas por la FDA para pacientes con niveles elevados de LDL-C, respaldadas por el ensayo CLEAR de resultados cardiovasculares con ~14,000 pacientes. La empresa está avanzando programas de inhibidores de la ATP citrato liasa (ACLIi) de próxima generación y persigue asociaciones internacionales y expansión comercial.
Esperion (NASDAQ: ESPR)은 2025년 3분기 재무 실적을 2025년 11월 6일 목요일 시장 개장 전 발표할 예정입니다.
경영진은 결과 및 비즈니스 업데이트를 논의하기 위해 동부 표준시 8:00에 라이브 웹캐스트를 개최합니다; 통화 후 약 두 시간 후 재생이 가능하며 회사 웹사이트에 약 90일간 보관됩니다.
Esperion은 LDL-C 수치가 상승한 환자들을 위한 FDA가 승인한 유일한 경구 복용형 비스타틴 요법을 상업화하는 상용 단계의 생물의약회사로, 약 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험으로 뒷받침됩니다. 회사는 차세대 ATP 구연산 시트르산 분해효소 억제제(ACLYi) 프로그램을 추진하고 국제 파트너십 및 상업 확장을 모색하고 있습니다.
Esperion (NASDAQ : ESPR) annoncera les résultats financiers du troisième trimestre 2025 avant l’ouverture du marché le jeudi 6 novembre 2025.
La direction animera une webdiffusion en direct à 8h00, heure de l’Est pour discuter des résultats et des mises à jour sur l’activité; un replay sera disponible environ deux heures après l’appel et sera archivé sur le site de l’entreprise pendant environ 90 jours.
Esperion est une société biopharmaceutique en phase commerciale qui commercialise les seules thérapies orales non statines approuvées par la FDA pour les patients présentant un LDL-C élevé, soutenues par l’essai CLEAR sur les résultats cardiovasculaires impliquant environ 14 000 patients. L’entreprise développe des programmes d’inhibiteurs de l’ATP citrate lyase (ACLYi) de nouvelle génération et recherche des partenariats internationaux et une expansion commerciale.
Esperion (NASDAQ: ESPR) wird die Finanzergebnisse des dritten Quartals 2025 vor Handelsbeginn am Donnerstag, dem 6. November 2025 bekannt geben.
Die Geschäftsführung wird um 8:00 Uhr ET einen Live-Webcast veranstalten, um Ergebnisse und Geschäft Updates zu besprechen; eine Wiederholung ist etwa zwei Stunden nach dem Anruf verfügbar und ca. 90 Tage auf der Unternehmenswebsite archiviert.
Esperion ist ein kommerziell tätiges Biopharma-Unternehmen, das die einzigen von der FDA zugelassenen oralen, einmal täglichen Nicht-Statin-Therapien für Patienten mit erhöhtem LDL-C vermarktet, gestützt durch die CLEAR-Studie mit ca. 14.000 Patienten. Das Unternehmen treibt Programme zum nächsten Generationen von ATP-Citrat-Lyase-Inhibitoren (ACLYi) voran und sucht internationale Partnerschaften sowie eine kommerzielle Expansion.
Esperion (بورصة ناسداك: ESPR) ستعلن عن نتائج الأعمال للربع الثالث من عام 2025 قبل افتتاح السوق يوم الخميس 6 نوفمبر 2025.
ستُدير الإدارة وبث حي على الويب في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة النتائج وتحديثات الأعمال؛ سيكون بالإمكان إعادة التشغيل حوالي ساعتين بعد المكالمة وأرشفتها على موقع الشركة لمدة ~90 يوماً.
Esperion هي شركة أدوية حيوية تجارية تسوق العلاجات الفموية غير الستاتينية الوحيدة المعتمدة من FDA للمرضى الذين يعانون من ارتفاع LDL-C، مدعومة بتجربة نتائج CLEAR القلبية الوعائية التي تشمل حوالي 14,000 مريض. تعمل الشركة على برامج مثبّطات إنزيم ACL (ACLYi) من الجيل القادم وتسعى لإشراك شركاء دوليين وتوسيع نطاق الأعمال تجارياً.
- None.
- None.
ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report Q3 2025 results?
What time is the Esperion (ESPR) Q3 2025 earnings webcast?
Where can investors access the Esperion (ESPR) webcast and replay?
What commercial products does Esperion (ESPR) market?
What clinical evidence supports Esperion's (ESPR) marketed therapies?
What R&D program is Esperion (ESPR) advancing beyond its marketed products?
